Clusters #3 (MET) and #5 (ROS1) involve gene alterations associated with ALK mutations; notably, MET gene amplification is a common mechanism of NSCLC drug resistance, while ROS1 shares significant structural and therapeutic similarities with ALK. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.